Product Overview

Hzymes has independently developed a Biological Fermentation semaglutide intermediate GLP-1(9-37).

Using AI-driven protein engineering, we modified expression strains to increase yield and atomic economy, and developed a highly specific enterokinase cleavage and purification process to achieve high purity and low impurities, followed by lyophilization. With a complete GMP Quality system and ton-scale production capacity.

Key Features

Ultra-High Purity

Manufactured to achieve ≥98% purity, supporting applications requiring more stringent quality specifications.

Low Impurity Profile

Developed using a highly specific enterokinase cleavage and purification process to minimize process-related impurities and enhance batch consistency.

Scalable Manufacturing

Produced through a biological fermentation process with ton-scale manufacturing capacity to support both development and commercial supply requirements.

Global Patent Freedom

Designed to support global market development with a patent-unrestricted supply strategy.

If appropriate, customers should independently assess applicable intellectual property requirements in their target markets.

GMP Quality System

Manufactured under a comprehensive GMP quality management system, with established controls for traceability and batch-to-batch consistency.

Applications

Semaglutide Synthesis

Used as a high-purity intermediate for semaglutide synthesis, supporting downstream peptide manufacturing processes.

Peptide Manufacturing

Suitable for peptide manufacturers seeking higher-purity GLP-1(9-37) intermediates for process development and production.

GLP-1 Product Development

Applicable to organizations involved in GLP-1-related research, development, and manufacturing activities that require consistent and scalable material supply.

Performance Data